Fabomotizol

Structural formula
General
Non-proprietary name	Fabomotizol
other names	5-ethoxy-2- (2-morpholin-4-ylethylsulfanyl) -1 H -benzimidazole ( IUPAC ); Obenoxazine;
Molecular formula	C 15 H 21 N 3 O 2 S
External identifiers / databases
PubChem	9862937
ChemSpider	8038633
Wikidata	Q2090655
Drug information
ATC code	N05 BX04
properties
Molar mass	307.41 g mol −1
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS hazard labeling ; no classification available
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Fabomotizol is an anxiolytic drug that was introduced in Russia as Afobazol (tablets) in the early 2000s . In addition to anxiolysis, the active ingredient has neuroprotective properties.

In contrast to treatment with benzodiazepines , sedation and muscle relaxation do not occur during treatment with fabomotizole. The mechanism of action has so far been little researched. There is evidence of an effect on GABA receptors , melatonin receptor antagonism and sigma receptor agonism. Fabomotizol is a moderate reversible MAO-A inhibitor and also interacts with the serotonergic system. This appears to be potentially responsible for the anti-anxiety effects. Clinical studies showed that Fabomotizol was well tolerated and is solidly effective in treating anxiety.

Individual evidence

↑ International Nonproprietary Names for Pharmaceutical Substances (INN) (= WHO Drug Information . No. 26 ). 1st edition. 2012, p. 63 ( Recommended International Nonproprietary Names: List 67 [PDF; accessed on March 21, 2015]).
↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
^ Fabomotizole hydrochloride , in: Martindale: The Complete Drug Reference, 38th Edition, Pharmaceutical Press, London 2014. p. 1073.
↑ GG Neznamov, SA Siuniakov, DV Chumakov, VK Bochkarev, SB Seredenin: Clinical study of the selective anxiolytic agent afobazol . In: Eksperimental'naia i klinicheskaia farmakologiia . 64, No. 2, 2001, pp. 15-9. PMID 11548440 .
↑ IV Silkina, TC Gan'shina, SB Seredin, RS Mirzoian: Gabaergic mechanism of cerebrovascular and neuroprotective effects of afobazole and picamilon . In: Eksperimental'naia i klinicheskaia farmakologiia . 68, No. 1, 2005, pp. 20-4. PMID 15786959 .
↑ SB Seredin, DS Melkumian, EA Val'dman, MA Iarkova, TC Seredina, MV Voronin, AS Lapitskaia: Effects of afobazole on the BDNF content in brain structures of inbred mice with different phenotypes of emotional stress reaction . In: Eksperimental'naia i klinicheskaia farmakologiia . 69, No. 3, 2006, pp. 3-6. PMID 16878488 .
↑ TA Antipova, DS Sapozhnikova, LIu Bakhtina, SB Seredenin: Selective anxiolytic afobazole increases the content of BDNF and NGF in cultured hippocampal HT-22 line neurons . In: Eksperimental'naia i klinicheskaia farmakologiia . 72, No. 1, 2009, pp. 12-4. PMID 19334503 .
↑ SB Seredenin, TA Antipova, MV Voronin, SY Kurchashova, AN Kuimov: Interaction of afobazole with sigma1-receptors . In: Bulletin of experimental biology and medicine . 148, No. 1, 2009, pp. 42-4. doi : 10.1007 / s10517-009-0624-x . PMID 19902093 .
↑ VE Medvedev, AP Trosnova, AV Dobrovol'skiĭ: Psychopharmacotherapy of anxiety disorders in patients with cardio-vascular diseases: the use of aphobazole . In: Zh Nevrol Psikhiatr Im SS Korsakova. . 107, No. 7, 2007, pp. 25-9. PMID 18379478 .

[1] International Nonproprietary Names for Pharmaceutical Substances (INN) (= WHO Drug Information . No. 26 ). 1st edition. 2012, p. 63 ( Recommended International Nonproprietary Names: List 67 [PDF; accessed on March 21, 2015]).

[NV-2] This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.

[3] Fabomotizole hydrochloride , in: Martindale: The Complete Drug Reference, 38th Edition, Pharmaceutical Press, London 2014. p. 1073.

[4] GG Neznamov, SA Siuniakov, DV Chumakov, VK Bochkarev, SB Seredenin: Clinical study of the selective anxiolytic agent afobazol . In: Eksperimental'naia i klinicheskaia farmakologiia . 64, No. 2, 2001, pp. 15-9. PMID 11548440 .

[5] IV Silkina, TC Gan'shina, SB Seredin, RS Mirzoian: Gabaergic mechanism of cerebrovascular and neuroprotective effects of afobazole and picamilon . In: Eksperimental'naia i klinicheskaia farmakologiia . 68, No. 1, 2005, pp. 20-4. PMID 15786959 .

[6] SB Seredin, DS Melkumian, EA Val'dman, MA Iarkova, TC Seredina, MV Voronin, AS Lapitskaia: Effects of afobazole on the BDNF content in brain structures of inbred mice with different phenotypes of emotional stress reaction . In: Eksperimental'naia i klinicheskaia farmakologiia . 69, No. 3, 2006, pp. 3-6. PMID 16878488 .

[7] TA Antipova, DS Sapozhnikova, LIu Bakhtina, SB Seredenin: Selective anxiolytic afobazole increases the content of BDNF and NGF in cultured hippocampal HT-22 line neurons . In: Eksperimental'naia i klinicheskaia farmakologiia . 72, No. 1, 2009, pp. 12-4. PMID 19334503 .

[8] SB Seredenin, TA Antipova, MV Voronin, SY Kurchashova, AN Kuimov: Interaction of afobazole with sigma1-receptors . In: Bulletin of experimental biology and medicine . 148, No. 1, 2009, pp. 42-4. doi : 10.1007 / s10517-009-0624-x . PMID 19902093 .

[9] VE Medvedev, AP Trosnova, AV Dobrovol'skiĭ: Psychopharmacotherapy of anxiety disorders in patients with cardio-vascular diseases: the use of aphobazole . In: Zh Nevrol Psikhiatr Im SS Korsakova. . 107, No. 7, 2007, pp. 25-9. PMID 18379478 .